Laura Huppert is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 120 publications with 1,739 citations (h-index 18); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1825 4th St Fl 3
San Francisco, CA 941432350
Telephone
415-353-7070Provider last certified this registry record 21 Sept 2022.
Clinical trials
- Quality of Life for Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease
Sponsor: University of California, San Francisco
- Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Sponsor: University of California, San Francisco
- ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Sponsor: Laura Huppert, MD, BA
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Company LTDProgram year20254 payments
- PFIZER INC.Program year20254 payments
- Gilead Sciences, Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
90.2%Aromatase Inhibitor84.1%Letrozole68%Exemestane17%Anastrozole14%Part D<11 patientsKinase inhibitor6.1%Verzenio100%Part D<11 patientsNervous system
9.8%Gabapentinoids9.8%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Implantation of engineered adipocytes suppresses tumor progression in cancer models
Nature Biotechnology
2025 - Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”